FreeStyle Libre 2 system, with optional, real-time glucose alarms. Now available for patients with diabetes age 4 and older

Unsurpassed 14-Day Accuracy1 For Patients With Diabetes Age 4 And Older

Meets the highest accuracy standards, so patients and caregivers can trust treatment decisions — even when glucose levels are rising or falling rapidly

Overall MARD§

(The lower the MARD, the more accurate the results)


% within ±20/20%


% in Zones A+B of Consensus Error Grid2


Outstanding Accuracy in the Low Glucose Range1


Low glucose range

<70 mg/dL (within ±20 mg/dL)

Improved Time in Range and A1c

FreeStyle Libre 2 system is clinically proven to help children and teenagers# achieve better glycemic control vs self-monitoring blood glucose (SMBG)3

More time in range**3

(70 mg/dL-180 mg/dL)


Average reduction
in A1c**3


#1 CGM in the US††


  • Outstanding accuracy in the low-glucose range1 when it matters the most
  • No confirmatory fingersticks* required for insulin dosing even when glucose is low, falling, or rapidly changing1

Optional, real-time glucose alarms

  • Glucose readings every minute2 alert patients the moment their readings are too high or too low
  • Excellent, reliable, alarm* performance in the low glucose range1

Easy for you and your patients**4

  • Discreet 14-day sensor is easy to apply and comfortable to wear4
  • More affordable CGM‡‡ at one-third the cost of other CGMs§§2
  • Easy to prescribe with no prior authorizations required‖‖

Have a sales representative tell you more

A rep can keep you informed about new and existing Abbott products

FreeStyle Libre link

All data presented is for age group 6 to 17 years old.
All values vs Yellow Springs Instruments (YSI).
*Fingersticks are required if your glucose alarms and readings do not match symptoms or when you see Check Blood Glucose symbol during the first 12 hours.
Notifications will only be received when alarms are turned on and the sensor is within 20 feet of the reading device.
Based on FDA iCGM special controls.
§MARD (mean absolute relative difference) is compared to reference YSI.
Calculated based on the percentage of system readings within ±20 mg/dL of YSI blood glucose values <70 mg/dL and within ±20% of YSI blood glucose values >70 mg/dL.
Calculated based on the number of CGM and YSI paired readings at glucose ranges <54-69 mg/dL and 56-69 mg/dL, respectively.
#FreeStyle Libre 2 system is indicated for use in people with diabetes age 4 and older.
**Data from this study was collected with the outside US version of FreeStyle Libre 14 day system. FreeStyle Libre 2 has the same features as FreeStyle Libre 14 day system with optional, real-time glucose alarms. Therefore, the study data is applicable to both products.
††Data based on the number of patients assigned to each manufacturer based on last filled prescription in US Retail Pharmacy and DME.
‡‡Based on a comparison of list prices of the FreeStyle Libre 2 system vs competitors' CGM systems. The actual cost to patients may or may not be lower than other CGM systems, depending on the amount covered by insurance, if any.
§§Based on a comparison of list prices of the FreeStyle Libre 2 system versus competitors CGM systems, assuming annual use of one receiver (or equivalent hardware) and quantity of transmitters and/or sensors according to use life.
‖‖This applies to commercially insured patients. This does not apply to beneficiaries of Medicare, Medicaid or other federal or state healthcare programs. Participating pharmacies are subject to change without notice.

References: 1. FreeStyle Libre 2 system User's Manual. 2. Data on file. Abbott Diabetes Care. 3. Campbell FM, Murphy NP, Stewart C, Biester T, Kordonouri 0. Outcomes of using flash glucose monitoring technology by children and young people with type 1 diabetes in a single arm study. Pediatr Diabetes. 2018;19(7):1294-1301. 4. Haak T, Hanaire H, Ajjan R, Hermanns N, Riveline JP, Rayman G. Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter, open-label randomized controlled trial. Diabetes Ther. 2017;8(1):55-73.

ADC-21509 v1.0 07/20